Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Deals

Shanghai’s EnjoSim Secures Tens of Millions in Pre-Series A Funding for Expansion

Fineline Cube Jan 15, 2024

EnjoSim, a Shanghai-based developer of microbiologic self-administration systems, has reportedly secured tens of millions of...

Company Deals

Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer

Fineline Cube Jan 15, 2024

Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview...

Company Drug

CARsgen Therapeutics Gets NMPA Approval for CAR-T Therapy CT011 in Hepatocellular Carcinoma

Fineline Cube Jan 15, 2024

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that it has received approval from...

Company Drug

Simcere Pharmaceutical Group Gets NMPA Green Light for USP1 Inhibitor SIM0501

Fineline Cube Jan 15, 2024

Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...

Company

Ant Insurance Reports 23% Surge in Health Insurance Payouts, Processing 4.69 Million Claims in 2023

Fineline Cube Jan 12, 2024

Ant Insurance, a platform integrated within Alibaba’s Alipay app, reported a 23% year-on-year increase in...

Company Deals

Myrobalan Therapeutics Secures $24 Million in Series A Funding with Strong Chinese Investor Support

Fineline Cube Jan 12, 2024

Myrobalan Therapeutics, a Massachusetts-based biotech firm, has successfully completed a $24 million Series A funding...

Company Drug

Huadong Medicine’s Relmapirazin Approval Filing Accepted by NMPA for GFR Measurement

Fineline Cube Jan 12, 2024

Huadong Medicine Co., Ltd (SHE: 000963), based in China, has announced that its market approval...

Company Medical Device

Lepu Medical Secures NMPA Approval for Innovative Coronary Intravascular Impact Waveguide Tube

Fineline Cube Jan 12, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a China-based provider of cardiovascular disease solutions,...

Company Deals

CORXEL Secures Licensing Rights for Biogen’s BIIB131 in Stroke Treatment

Fineline Cube Jan 12, 2024

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has secured a...

Company

Boehringer Ingelheim Expands Greek Facility to Boost Production of Jardiance and Other Medications

Fineline Cube Jan 12, 2024

Boehringer Ingelheim (BI), headquartered in Germany, has commenced the expansion of its manufacturing facility in...

Company

Fosun Kite and Medi Cover Launch First Value-Based Payment Plan for Lymphoma Treatment

Fineline Cube Jan 12, 2024

Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG:...

Company Drug

Novo Nordisk’s IcoSema Shows Promise in Late-Stage Trial for Type 2 Diabetes Management

Fineline Cube Jan 12, 2024

Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...

Company Drug

AbbVie’s Lutikizumab Advances to Phase III for Hidradenitis Suppurativa After Positive Mid-Stage Results

Fineline Cube Jan 12, 2024

AbbVie (NYSE: ABBV) has announced the progression of lutikizumab to Phase III clinical trials following...

Company

Changchun High & New Technology to Transfer 7.42% Stake to Ex-Wife in Divorce Settlement

Fineline Cube Jan 12, 2024

Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has announced plans to transfer...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for Combined Phase Ib/II Study of BAT7104 and BAT4706

Fineline Cube Jan 12, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a Chinese biopharmaceutical company, has announced that it has received...

Company Drug

Eisai’s Lemborexant Sleep Aid Lemborexant Filed for NMPA Approval in China

Fineline Cube Jan 12, 2024

The China Center for Drug Evaluation (CDE) website has indicated that Japan-based Eisai (TYO: 4523)...

Company

Astellas Pharma Appoints Zhao Ping as Chairman of China Operations

Fineline Cube Jan 12, 2024

Effective January 15, 2024, Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has appointed...

Company Deals

Keylights Biotechnology Raises $14 Million in Series B to Expand IVD Instrument Range

Fineline Cube Jan 12, 2024

Keylights Biotechnology Co., Ltd., a leading in vitro diagnostic (IVD) instruments manufacturer headquartered in Shenzhen,...

Company Drug

Joincare Pharmaceutical’s Partner Fermion Gets NMPA Green Light for Pain Drug Clinical Study

Fineline Cube Jan 12, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced that...

Company Deals

Gansu Deshengtang Partners with RELEX Solutions to Enhance Supply Chain Efficiency

Fineline Cube Jan 12, 2024

Gansu Deshengtang Medical Science and Technology Group Co., Ltd, a prominent Chinese healthcare group, has...

Posts pagination

1 … 468 469 470 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.